Literature DB >> 16949974

Use of anteriorly based pericranial flap in frontal sinus obliteration.

Ali Moshaver1, Jeffery R Harris, Hadi Seikaly.   

Abstract

OBJECTIVE: In an era of endoscopic sinus surgery, frontal sinus obliteration continues to remain an important treatment option in chronic frontal sinus disease. Numerous avascular obliterative materials including fat, muscle, cancellous bone, and hydroxyapatite have been used in this procedure. In this article, we describe a vascularized anteriorly based pericranial flap to obliterate frontal sinus. STUDY
DESIGN: Retrospective chart review of patients referred to tertiary care hospital between 1996 and 2003.
METHODS: Records of the patients who underwent this procedure were reviewed. Demographics, indications, and immediate and late complications were recorded. A phone questionnaire was used to assess patient satisfaction with the outcome.
RESULTS: A total of 12 patients underwent frontal sinus obliteration with this technique. Mean follow-up was 40 months. None of the patients developed recurrent frontal sinusitis. All of the patients were pleased with the outcome.
CONCLUSION: Pericranial flap is a highly vascularized flap that is easily harvested and is an effective and viable modality for obliterating frontal sinus. EBM RATING: C-4.

Entities:  

Mesh:

Year:  2006        PMID: 16949974     DOI: 10.1016/j.otohns.2006.03.041

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  A simple classification of cranial-nasal-orbital communicating tumors that facilitate choice of surgical approaches: analysis of a series of 32 cases.

Authors:  Yue-Fei Deng; Bing-Xi Lei; Mei-Guang Zheng; Yi-Qing Zheng; Wei-Liang Chen; Yu-Qing Lan
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-26       Impact factor: 2.503

2.  Cranialization of the frontal sinus for secondary mucocele prevention following open surgery for benign frontal lesions.

Authors:  Gilad Horowitz; Moran Amit; Oded Ben-Ari; Ziv Gil; Abraham Abergel; Nevo Margalit; Oren Cavel; Oshri Wasserzug; Dan M Fliss
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.